These data demonstrating the synergistic effects of ganetespib-induced degradation of HSP90 client proteins and lapatinib-induced inhibition of apical RTK activity on various levels of the RTK pathways support potential clinical trials testing the combined treatment regimen of ganetespib + lapatinib in ErbB2+ breast cancer patients. Here, ERBB2 is linked to breast carcinoma.